The disorder of B cells is one of the hallmarks of systemic lupus erythematosus (SLE). The activation state indicated by CD86 of B cells from SLE is well known, while the defect of regulatory B cells mediated by CD1d is also responsible for the process of SLE. In the present study, we focused on the relationship between B cell activation mediated by CD86 and B cell regulatory function mediated by CD1d. Our results showed that the level of CD1d in B cells was decreased during the early stages of B6.MRLlpr SLE mice and imiquimod-treated (IMQ-treated) mice, while the level of CD86 was significantly increased at the late stage. Moreover, the expression of CD1d showed a significantly negative correlation with CD86 level in B cells from IMQ-treated mice (r = −05741; P = 0.0022), B6.MRLlpr mice (r = −0.7091; P = 0.0268), and SLE patients (r = −0.4125; P = 0.0404). The in vivo and in vitro experiments with splenocytes demonstrated that CD1d signaling pathway could inhibit toll-like receptor 7 (TLR7)-induced CD86 expression of B cells. Further studies showed that this relationship also affected antibody production. Thus, our results confirmed the association of CD1d and CD86 levels in B cells from SLE, and demonstrated the importance to preserve the immunoregulatory function of B cells mediated by CD1d in the progression of SLE.
Introduction
It has been demonstrated that both environmental [1] and genetic factors [2] contribute to the pathogenesis of systemic lupus erythematosus (SLE). The combination of these factors induces the breakdown of B and T cells tolerance [3] , the production of autoreactive antibodies as well as the expansion of inflammatory cytokines, and ultimately results in organ damage [4] . However, the mechanism from the pathogenic factor to the pathogenesis of SLE is still unknown. Furthermore, which pathological mechanism happens first or which is the cause or the effect in the entire course of SLE is not yet understood. Although much progress has been made in the research of SLE pathogenesis over the past decades, the exact cause of SLE is not fully understood and an effective treatment of SLE is still lacking.
With plenty of studies in the pathogenesis of SLE, there is no doubt that B cells play a key role in the disease process underlying SLE [5] . B cells not only contribute to the formation of autoantibody and immune complex, but also contribute to the pathogenesis of SLE by antigen presentation [6] and cytokine activation [7] [8] [9] . Specially, the activation of B cell is one of the characteristics of SLE [10] and the generation of antinuclear antibodies also attributes to the uncontrolled over-activated B cells [11] . Previous studies have demonstrated that the increased level of co-stimulatory molecule CD86, but not of CD80, is correlated with the increased possibility of autoimmune antibody formation and the pathological characteristics of SLE [11] [12] [13] . The immune complexes deposit leads to tissue damage in many parts of the body [4] . This could be the reason of the efficient treatment for SLE by B cell target therapy [5, 14] . But whether the over-expressed CD86 is responsible for B cell defect or it is just a manifestation of B cell defect underlying SLE has not been explored.
In addition, the defect of immunoregulatory function of B cells [15] may also contribute to the process of SLE [16, 17] . Previous studies have revealed the importance of the regulatory B cells in SLE mice [16] and SLE patients [17] . One subset of the regulatory B cell has been characterized as CD5
+

CD1d
+
IL-10
+ B cell [16, 18] . Regulatory B cells function not only by the secretion of interleukin-10 (IL-10) [19, 20] , but also by interaction with invariant natural killer T (iNKT) cell through CD1d [6] . CD1d is constitutively expressed in antigen processing cells (APCs), mainly including macrophages [21] , dendritic cells (DCs) [22] , and B cells [23] . It has been demonstrated that normal CD1d level in B cells was efficient for the regulatory function of both B cells and iNKT cells in SLE [6] . Our recent study has also revealed the decreased level of CD1d in B cells from SLE mice. Toll-like receptor (TLR)-induced microRNA-155 could also decrease the CD1d level of APCs, especially of B cells [24] . All these findings indicate that the immunoregulatory function of B cell mediated by CD1d contributes to SLE pathogenesis [25] , which may explain the disappointing efficacy of B cell-directed therapies in SLE [14] . Although the loss of immunoregulatory function of B cell exits in SLE [24] , it is still unclear whether this defect is a manifestation or a reason for the onset and progression of SLE.
In the present study, to explore the pivotal role of B cells associated with immunoregulatory function and activation in the process of SLE, we detected the levels of CD1d and CD86 in B cells during the entire course of SLE with murine lupus models. Our results showed that CD1d level was decreased in B cells during the early stages of B6. MRLlpr SLE mice, and CD86 expression was significantly increased only at the late stage. The same change was observed in DCs. To further verify this phenomenon, we further examined the levels of CD1d and CD86 in imiquimod-treated (IMQ-treated) mice. Similar results were obtained in B cells but not in DCs. The level of CD1d in B cells showed a significantly negative correlation with CD86 level in IMQ-treated mice, B6.MRLlpr SLE mice, and SLE patients. Lastly, the in vitro and in vivo experiment demonstrated that CD1d signaling pathway could inhibit TLR7-induced CD86 expression of B cells. And further results showed that this relationship also affects antibody production.
Materials and Methods
Mice
Female C57BL/6 and sex and age-matched B6.MRL-Faslpr/J lupusprone mice were purchased from Model Animal Research Center of Nanjing University (Nanjing, China). All mice were bred and housed under specific pathogen-free conditions. The procedures were approved by the Animal Care Commission of Nanjing University. B6.MRL-Faslpr/J lupus-prone mice and the control mice were euthanized at the indicated time.
For lupus model induction, 7-to 8-week-old female C57BL/6 mice were topically treated with 5% IMQ cream (3M Health Care, St Paul, USA) for indicated time as described previously [26] . KN7000 is the most effective agonist of CD1d and iNKT cells, as well as a ligand of TLR7. For KRN7000 treatment, IMQ creamtreated mice were administrated three times per week i.p. with 400 μg KRN7000 or the same volume of PBS (0.5 ml) as the control.
Human samples
Whole blood samples were collected from SLE patients (n = 20) and healthy controls (n = 16). The study protocols were approved by the Institutional Medical Ethics Review Board of Nanjing First Hospital and the consent forms were obtained from the SLE patients and healthy controls. All of the SLE patients were diagnosed according to the revised criteria issued by the American College of Rheumatology in 1997. Disease activity was determined using the SLE Disease Activity Index (SLEDAI) and the cut-off for active disease classification was decided to be ≥8. The clinical information of SLE patients was shown in Supplementary Table S1 .
Isolation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated from human blood sample and mouse blood sample by Ficoll density gradient centrifugation according to the protocol of ficoll-hypaque solution (Tianjin Hao Yang Biological Manufacture Company, Tianjin, China).
Generation of mouse splenocytes and B cells
Mouse spleen was separated and the total splenic cells were depleted of red blood cells by lysis in an ammonium chloride-containing buffer. Then, splenocytes were cultured in flat-bottom plates (Corning, Corning, USA) at a density of 1 × 10 6 cells/ml in RPMI 1640 supplemented with 10% FBS and antibiotics (penicillin 100 U/ml, streptomycin 100 μg/ml; Invitrogen, Carlsbad, USA) in a humidified atmosphere of 5% CO 2 at 37°C for the subsequent experiments. Mouse iNKT cells were depleted from the mouse splenocytes with the NK1.1 + iNKT cell isolation kit (MiltenyiBiotec, San Diego, USA) according to the manufacturer's protocol. Mouse B cells were separated with anti-CD45R (B220) antibody-coated microbeads (MiltenyiBiotec) according to the manufacturer's protocol.
Chemicals and ligands
The stock solution of KRN7000 (Cayman Chemical, Ann Arbor, USA) was prepared in DMSO and the stock solution of R848 (Enzo Life Science, New York, USA) was prepared in ddH 2 O. Anti-mouse CD1d antibody was purchased from eBioscience (San Diego, USA).
RNA extraction and quantitative real-time PCR
Total RNA was extracted with Trizol reagent (Invitrogen) according to the manufacturer's instructions. Real-time PCR assay was performed using the Applied Biosystems StepOne Sequence Detection System (Applied Biosystems, Foster City, USA) using SYBR green dye (Invitrogen) according to the manufacturer's instructions. Relative expression of the genes was calculated by using 2 −ΔΔCT formula using GAPDH as the control. The values reported are the mean of at least three technical replicates. Primers used are presented in Supplementary Table S2 .
Flow cytometry
Anti-mouse CD1d-APC, CD1d-PE, CD86-APC, CD86-PE, CD86-FITC, CD11c-FITC, F4/80-FITC, MHCII-APC, anti-human/mouse B220-FITC, anti-human CD1d-APC, CD86-PE, and CD19-FITC were all purchased from eBioscience. Prepared cells were washed with PBS and incubated with antibody for 30 min before being detected. Flow cytometry was performed on FACSCalibur (BD Biosciences, Franklin Lakes, USA) and data were analyzed using FlowJo (Tree Star, San Carlos, USA).
Western blot analysis
The cells were lysed with lysis buffer. Total lysates were resolved by SDS-PAGE and transferred to PVDF membranes (Millipore, Bedford, USA). Membranes were incubated with antibodies against p-SHP-1, SHP-1, p-SHP-2, and SHP-2 (Bioworld Technology, St Louis, USA), followed by incubation with the corresponding secondary antibodies. Protein bands were finally visualized using ECL Plus western blotting detection reagents (Millipore). GAPDH was served as an internal control. Each blot was a representative of three independent experiments.
Proteinuria analyses
Total urinary protein was determined using a mouse albumin ELISA quantitation set (Bethyl Laboratories, Montgomery, USA) according to the manufacturer's instructions and the urine was applied at dilutions of 1:100 [16] . Absorbance was determined using an ELx-800 Universal Microplate Reader (Biotek, Winooski, USA).
Detection of anti-DNA antibody
Anti-dsDNA IgG was measured by ELISA using a mouse antidsDNA IgG kit according to the manufacturer's instructions (Alpha Diagnostic, Paramus, USA). Absorbance was determined using an ELx-800 Universal Microplate Reader.
Statistical analyses
Statistical significance between two groups was determined with unpaired Student's t tests. P values <0.05 were considered statistically significant. The correlation results were determined by Spearman's correlation test. GraphPad Prism software (San Diego, USA) was used for statistical calculation.
Results
Early decreased CD1d level of B cells in the process of B6.MRLlpr SLE mice
It has been reported that the defect of CD1d was responsible for the pathogenesis of SLE [6, 25] . And our previous study also demonstrated the decreased level of CD1d in B cells under SLE condition in B6.MRLlpr SLE mice [24] . To explore the critical function of CD1d in SLE, its expression in the entire course of SLE with B6. MRLlpr SLE mice was examined. B220 + cell subset was indicated as B cells (Supplementary Fig. S1A ). Above all, the decreased CD1d level was examined in B cells at 6 weeks of SLE mice, and the low level could be detected until 21 weeks when the proteinuria from SLE mice was significantly higher compared to B6 mice ( Fig. 1A and Supplementary Fig. S1B ). These results suggested an early decrease of CD1d level in the process of SLE. CD1d level in DCs and macrophages, the other two classical APCs were also detected. The CD1d expression in DCs also was decreased at an early stage of the disease progression ( Supplementary Fig. S1A and Fig. 1B ). However, the CD1d level showed an increased trend in macrophages in the entire course of SLE disease (Fig. 1C) .
CD86 level was increased in B cells at the late stage of B6.MRLlpr SLE mice disease progression
Aberrant activation of B cells directly contributes to the progress of SLE [27] . Therefore, the activation state of B cells was evaluated by examining the level of CD86 in the entire course of SLE according to the previous reports [11, 13] . Interestingly, the CD86 level in B cells was increased at a relative late stage in the course of SLE disease. And the trend of increase had a significant difference until 21 weeks when the mice entered the period of morbidity ( Fig. 2A) .
These results suggested that CD86 in B cells was increased at a relative late stage of SLE progression. At the same time, CD86 levels in DCs and macrophages were also examined. As shown in Fig. 2B , the expression of CD86 in DCs from SLE mice showed no significant difference despite of the trend of increase. While the CD86 level was increased significantly in macrophages from 16 weeks to 21 weeks (Fig. 2C) . Thus, the results from B6.MRLlpr SLE mice demonstrated the difference of APCs and indicated distinct functions of CD1d and CD86 in B cells.
IMQ-treated mice showed decreased CD1d levels and subsequent increased CD86 expression
To further investigate this phenomenon, another SLE-like mice model was constructed with IMQ, a TLR7 agonist. As previously described [26, 28] , the B6 mice were topically treated with IMQ for indicated weeks until being sacrificed. Expectedly, the CD1d expression in B cells from IMQ-treated mice showed a remarkable decrease at week 7, while the CD86 expression was significantly increased from week 10 ( Fig. 3A) . In addition, the TLR7 signaling pathway decreased the percentage of B220 mice. A decreased CD1d expression and an increased CD86 expression were also found at RNA level in B cells from IMQ-treated mice (Fig. 3D) , but the mRNA levels of CD80 were not significantly changed. It has been reported that the function of CD1d is associated with IL-10 [20, 29] , therefore the mRNA level of IL-10 was also detected. The expression of IL-10 in B cells also showed little difference. In addition, the results from total splenocytes showed significantly decreased mRNA level of CD1d, but the mRNA levels of CD86, CD80, and IL-10 were not significantly altered ( Supplementary Fig. S3A,B) . Lastly, the CD1d and CD86 expressions in PBMCs were detected. Interestingly, CD1d expression was decreased in PBMCs at week 7, and the level of CD86 showed significant difference at week 13. Besides, the mRNA levels of CD80 and IL-10 were increased at week 7 ( Supplementary Fig. S3C ). Our results demonstrated the early decreased level of CD1d and the late increased CD86 expression in the course of SLE mice.
CD1d expression in B cells was negatively correlated with CD86 level in IMQ-treated mice
In spite of the interesting results above, whether the level of CD1d was related to the expression of CD86 was unclear. Most excitingly, our results revealed a significantly negative correlation between CD1d and CD86 levels in B cells from IMQ-treated mice (Fig. 4A) . But the positive correlation between CD1d and CD86 expression was found in DCs (Fig. 4B) . In spite of the increased level of MHCII, there is no correlation between MHCII and CD1d ( Supplementary Fig. S4 ). Importantly, a negative correlation was also found between CD1d and CD86 levels in B cells from B6.MRLlpr mice (Fig. 4C) . These results suggest that the early decreased CD1d may be responsible for the increased level of CD86 in B cells.
CD1d level showed negative correlation with CD86 expression in B cells from SLE patients
The levels of CD86 and CD1d in B cells from human PBMCs were further detected. PBMCs from SLE patients showed increased percentage of CD19 + B cell compared with PBMCs from healthy controls ( Fig. 5A and Supplementary Fig. S5A ), which was consistent with our previous results [30] . Similar to previous results [11, 30] , SLE patients showed increased percentage of CD19 + CD86 + B cells ( Fig. 5B and Supplementary Fig. S5B ). The level of CD86 in B cells from SLE patients was higher than that from healthy controls (Fig. 5B) . Interestingly, the level of CD1d was decreased in B cells from SLE patients [6] , although the percentage of CD19
cells was not significantly different ( Fig. 5C and Supplementary Fig.  S5B ). Most importantly, our results showed a significantly negative correlation between CD1d level and CD86 level in human B cells (Fig. 5D) . These results indicated that the CD1d could control CD86 expression in B cells, and that defective CD1d expression in SLE patients was responsible for higher CD86 expression. Thus, what we found in humans and mice suggested that the level of CD1d had a negative correlation with CD86 expression in B cells, and that the decreased CD1d expression of B cells under SLE condition was responsible for the over-expression of CD86.
CD1d signaling pathway might inhibit CD86 expression through SHP-2 signaling pathway
To explore whether CD1d was related to the level of CD86 in B cells, the total splenocytes were isolated from B6 mice. The cells were seeded in 48-well plates for the following experiments. After being stimulated with indicated agonist for 5 h, the cells were collected for CD86 detection at RNA level. The results showed that CD86 expression was increased after stimulation with 500 ng/ml of TLR7 agonist R848, but the addition of 100 ng/ml of KRN7000 inhibited the effect of TLR7 ligation. KRN7000 was an effective agonist of CD1d and iNKT cells. More interestingly, pretreatment with anti-CD1d antibody weakened The activation of SHP-1 and SHP-2 was detected by western blot analysis. One representative blot of three independent experiments was shown. (F) KRN7000 was administrated in IMQ-treated mice (n = 5). CD86 level was detected. Bars show the mean ± SEM from three independent experiments. *P < 0.5, **P < 0.01, and ***P < 0.001.
this effect (Fig. 6A) . We did not find this effect on the CD80 level (Fig. 6B ). We also found decreased level of IL-10 after CD1d ligation (Fig. 6C) . Interestingly, flow cytometry analysis results showed that both the percentage and level of CD86 were increased in B cells after pretreatment with anti-CD1d antibody, but not in DCs (Fig. 6D) .
It has been reported that the inhibitory effects of SH2-containing phosphotyrosine phosphatase-1/2 (SHP-1/2) are mediated by Fcγ receptor and other membrane protein [31] [32] [33] [34] , so it will be interesting to determine whether the ligation of CD1d is associated with SHP-1/2 signaling pathway. As shown in Fig. 6E , the activation of SHP-2, but not of SHP-1, was decreased after pretreatment with anti-CD1d antibody compared with stimulation with R848 and KRN7000 in mice splenocytes. It was found that the addition of KRN7000 could also decrease CD86 expression in vivo (Fig. 6F) . However, no significant difference was found in CD86 expression and SHP-2 activation in splenocytes without iNKT cells ( Supplementary Fig. S6A,B) . No significant change was found in CD86 expression and SHP-2 activation with B cell alone ( Supplementary Fig. 6C,D) .
Thus, these results demonstrated that the ligation of CD1d might inhibit TLR7-induced CD86 expression in B cells through SHP-2 signaling pathway. Our results suggested that the normal CD1d level of B cells might be responsible for the control of CD86 expression.
CD1d signaling pathway affected auto-antibody production
Over-production of auto-antibody is the hallmark of SLE, and it was reported that the over-expression of CD86 was correlated with the auto-antibody production in SLE. Therefore, we further detected how CD1d signaling affects antibody production. The in vitro assay in splenocytes demonstrated that the addition of anti-CD1d antibody could enhance R848-and KRN7000-induced auto-antibody production (Fig. 7A) . The in vivo experiment showed that KRN7000 could decrease auto-antibody production in lupus model (Fig. 7B) . More importantly, the CD1d level was found to be negatively correlated with the production of autoantibody (Fig. 7C) . These results demonstrated that the CD1d signaling pathway also affected auto-antibody production.
Discussion
B cells are one of the participants in the progression of SLE. Aberrant activation of B cells directly contributes to the development of SLE, while the immunoregulatory function of B cells affirms their beneficial role in lupus. But few studies have been carried out to explore the relationship between these two aspects. In the present study, we demonstrated that the levels of CD1d and CD86 in B cells had a negative correlation under SLE condition. The early decrease of CD1d level in B cells might be the reason for the increased expression of CD86 in SLE. These results were confirmed in both B6.MRLlpr SLE mice and IMQ-treated mice. Our in vitro experiments also demonstrated this association between CD1d and CD86 in B cells. The increased level of CD86 in B cells is correlated with the auto-antibody production in SLE [13] , thus our results might imply that CD1d could be the checkpoint of B cell activation and subsequent auto-antibody production. In addition, the defect of CD1d in B cells could be the reason of lower activation threshold of B cells and the increased emergence of autoreactive B cells [35] . These results demonstrated the importance to preserve the immune regulatory function mediated by CD1d B cells in the progression of SLE.
It has been demonstrated that CD1d is responsible for the progression of SLE. Yang et al. [36] found that CD1d deficiency could exacerbate inflammatory dermatitis in MRL-lpr/lpr mice. The immunoregulatory function of CD1d is helpful for lupus nephritis in the hydrocarbon oil-Induced mice [25] . The immunoregulatory function of CD1d is mediated by the crosstalk between APCs and iNKT cells. Actually, it has been suggested that iNKT cells can inhibit autoreactive B cells in a CD1d-dependent manner [37] , which is consistent with our in vitro experiment results. However, previous studies have also reported that CD1d and iNKT could enhance B cell activation and auto-antibody production [38, 39] . Moreover, Lang et al. [40] revealed that the level of CD1d affects B cell memory but does not enhance antibody production [40] . All these suggested the complexity of the roles of CD1d in SLE. Because of the complex roles of iNKT from different strains of mice and a distinct effect of CD1d at different stages of lupus model [41, 42] , further studies are still needed to make it clear.
In addition, alterations of CD1d and CD86 were also found in DCs and macrophages. The CD1d level in DCs changed similarly as in B cells from B6.MRLlpr SLE mice, while the results were different in IMQ-treated mice. CD86 expression in DCs showed no significant difference, but showed similar significant difference as in B cells from IMQ-treated mice. The CD1d and CD86 expressions in macrophages were also different from those in DCs and B cells. So the different expression trends in these APCs reflect their distinct functions and roles in the pathogenesis of SLE. Thus, further research is required to explain the role of CD1d in DCs and macrophages.
The interaction between iNKT cells and B cells mediated by CD1d was reported to play an immunoregulatory role in the early stage of SLE, while T cells promote B cell maturation and production of antinuclear auto-antibodies with increased CD86 expression. The normal CD1d signaling pathway interacting with iNKT cells might control CD86 level through the SHP-2 signaling pathway, while defective CD1d in B cells from SLE was associated with CD86 over-expression (Fig. 8) . This diagram shows that the defect of immunoregulatory function mediated by CD1d in SLE might be the reason of B cell activation mediated by CD86.
In summary, our study demonstrated the CD1d expression in B cells, DCs, and macrophages during the SLE course. CD1d level in B cells showed a negative correlation with CD86 expression. So the early deficiency in CD1d expression might be responsible for the over-expression of CD86 in B cells during the progression of SLE. More importantly, our results demonstrated the importance to preserve the immunoregulatory function of B cells mediated by CD1d in the development of SLE.
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